

THIS ISSUE'S AUTHORS

LINDA CHANG, M.D., is professor of medicine at the John A. Burns School of Medicine at the University of Hawaii and codirector of the University of Hawaii–Queen's Medical Center Magnetic Resonance Research Program. She has extensive experience in clinical neuroscience research, particularly in the application of advanced neuroimaging techniques to study brain changes associated with HIV infection, substance abuse, brain development, and aging. Dr. Chang serves on the *Science & Practice Perspectives* Editorial Board.

DONALD F. DANSEREAU, PH.D., is professor of psychology at Texas Christian University in Fort Worth and the associate director for cognitive interventions at the Institute of Behavioral Research. His publications include more than 160 papers that focus primarily on cognitive approaches for improving education, motivation, and engagement in drug treatment interventions. His current interests include the development of theoretical models and practical strategies for acquiring and using complex information, especially in organizational settings.

JOANNA S. FOWLER, PH.D., is a senior chemist at Brookhaven National Laboratory and director of the Brookhaven Center for Translational Neuroimaging. Her research interests include rapid organic synthesis and radiotracer design and development for imaging-specific molecular targets, imaging monoamine oxidase in studies of the effects of tobacco smoke exposure on the human brain and peripheral organs, and the use of positron emission tomography to study drug pharmacokinetics and pharmacodynamics.

JAY M. HANSEN is executive director of Prairie Ridge Addiction Treatment Services. He has guided the organization through program planning and development, facility development and relocation, initial and ongoing licensure, a transition to managed care, and community engagement. Most recently, Mr. Hansen has spearheaded the agency's continuous quality improvement effort. He is an active member of the Iowa Substance Abuse Program Directors' Association, which is working to improve the community-based prevention and treatment system in Iowa. Mr. Hansen has more than 30 years of experience in the substance abuse prevention and treatment field.

CHERYL A. KASSED, PH.D., M.S.P.H., is a senior research leader, writer, and editor at Thomson Medstat, Inc. She focuses on co-occurring substance abuse and mental illness, advances in pharmacology, adolescent brain development, and dementias. Dr. Kassed has more than 15 years of bench science and data analysis experience.

FRANK McCORRY, PH.D., is director of the Practice Improvement and Performance Unit at the New York State Office of Alcoholism and Substance Abuse Services. He is responsible for clinical policy and practice improvement issues, particularly in the areas of public health, co-occurring mental health and addictive disorders, and managed care. He is the principal investigator for a NIDA State infrastructure grant to enhance New York's capacity to foster the adoption of evidence-based practices. Dr. McCorry is chair of the Washington Circle Group, an initiative sponsored by the Substance Abuse and Mental Health Services Administration to develop substance abuse performance measures for use in managed care and public sector settings. He also is co-chair of the National Quality Forum's Evidence-Based Practices to Treat Substance Use Disorders Steering Committee.

CONALL M. O'CLEIRIGH, PH.D., is a clinical fellow in psychology at Massachusetts General Hospital/Harvard Medical School and a behavioral scientist at the Fenway Institute. His areas of research interest include adapting cognitive-behavioral therapy to address issues of depression and treatment adherence. His current projects include developing and testing treatments to address primary and secondary prevention issues associated with HIV.

MICHAEL W. OTTO, PH.D., is professor of psychology at Boston University and director of the Center for Anxiety and Related Disorders. Dr. Otto conducts intervention and translational research projects targeting a wide range of affective and substance use disorders. His current projects include NIDA-funded treatment outcome investigations of novel cognitive-behavioral treatment strategies, including medication augmentation strategies, for substance use disorders.

MARK H. POLLACK, M.D., is director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School. His areas of clinical and research interest include the acute and long-term course, pathophysiology, and treatment of patients with anxiety disorders, substance dependence, and associated comorbidities. Dr. Pollack has been funded by NIDA for investigations of novel treatment strategies for central nervous system correlates of chronic substance dependence.

D. DWAYNE SIMPSON, PH.D., is director of the Institute of Behavioral Research and the S.B. Sells Professor of Psychology at Texas Christian University in Fort Worth. His work is reported in more than 250 publications and includes several large-scale and longitudinal national evaluations. It now focuses on treatment process (including the integration of client assessments and strategic interventions), the transfer of research to practice, and the role of organizational functioning in treatment improvement. He is a fellow in the American Psychological Association and the American Psychological Society, and an international advisor on drug abuse treatment and related policy issues.

NORA D. VOLKOW, M.D., is director of the National Institute on Drug Abuse and is an international leader in drug addiction research and brain imaging. Dr. Volkow came to NIDA from Brookhaven National Laboratory, where she held concurrent positions as associate director for life sciences, director of nuclear medicine, and director of the NIDA–Department of Energy Regional Neuroimaging Center. In addition, Dr. Volkow was a professor in the Department of Psychiatry and associate dean of the medical school at the State University of New York–Stony Brook. At Brookhaven, Dr. Volkow was the first to use imaging to investigate neurochemical changes that occur during drug addiction. She investigated the neurochemical mechanisms that influence the way individuals respond to drugs of abuse and the potential link to vulnerability to drug abuse, alcoholism, and other impulse behaviors.

& PANEL RESPONDENTS

PETER BANYS, M.D., is a health sciences clinical professor of psychiatry at the University of California, San Francisco (UCSF). He is director of the substance abuse programs at the Veterans Affairs (VA) Medical Center and director of the VA/UCSF Substance Abuse Physician Fellowship Program. He is a past president of the California Society of Addiction Medicine and a member of the executive board of the American Society of Addiction Medicine. He recently returned from Vietnam, where he consulted with health officials about the intersecting epidemics of HIV infection and injection drug use.

LINDA BRADSHAW, M.A., is a program manager at Changepoint, Inc., in Portland, Oregon. She has been working in the addiction treatment and prevention field since 1973. For the past 20 years, she has been assisting agencies in obtaining and maintaining their State certifications and accreditations from the Joint Commission on Accreditation of Healthcare Organizations and the Commission on Accreditation of Rehabilitation Facilities. She has supervised a wide continuum of services, from outpatient to residential, for both adolescent and adult populations.

FELIPE CASTRO, M.S.W., PH.D., is professor of clinical psychology in the Department of Psychology, Arizona State University. Dr. Castro's research areas include the study of substance abuse risk and protective factors, especially those having a cultural origin, and the design of prevention and treatment interventions for racial/ethnic minorities. He is particularly interested in factors that promote successful recovery from addiction to stimulants, including methamphetamine and cocaine. Dr. Castro also serves as an associate editor for the journals *Prevention Science* and *American Journal of Public Health*.

DEBORAH GARNICK, SC.D., is a professor at the Institute for Behavioral Health at The Heller School for Social Policy and Management at Brandeis University and associate dean of academic personnel. Dr. Garnick leads the Brandeis team in a collaboration to specify the national outcome measures for behavioral health in a project funded by the Substance Abuse and Mental Health

Services Administration. She also directs an effort to extend performance measures for substance abuse services developed for commercial managed care plans to public health systems through research grants funded by NIDA and the National Institute on Alcohol Abuse and Alcoholism. In addition, she is a member of the Washington Circle Group and leads their work group on public sector performance measures for substance abuse.

DANIEL R. KIVLAHAN, PH.D., is director of the U.S. Department of Veterans Affairs (VA) National Center of Excellence in Substance Abuse Treatment and Education at the VA Puget Sound Health Care System, where he has been an addiction treatment clinician and investigator since 1985. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington and clinical coordinator of the VA Substance Use Disorder Quality Enhancement Research Initiative. He has been actively involved in developing national performance measures. Among his recent publications are reports from the COMBINE Study for treatment of alcohol dependence and several other reports on alcohol screening in primary care settings, including validation of the AUDIT-C.

MICHAEL LEVY, PH.D., is a licensed psychologist who has worked for more than 20 years with clients who suffer from substance abuse and other disorders. He has directed locked inpatient psychiatric units, including one for clients with co-occurring disorders, and has clinically managed and overseen quality improvement processes for detoxification, outpatient, and other substance abuse treatment programs. He has also written numerous articles and book chapters and has conducted workshops on working with substance-abusing clients.

PAUL LINDE, M.D., is associate clinical professor of psychiatry at the University of California, San Francisco School of Medicine and an attending psychiatrist in the Psychiatric Emergency Services and the STOP and Stonewall outpatient stimulant addiction clinics at San Francisco General Hospital. Author of a nonfiction book entitled *Of Spirits and Madness: An American Psychiatrist in Africa*, published in 2002, Dr. Linde is prepar-

ing his next book, *Danger to Self: The Making of a 21st Century Psychiatrist*, for publication by the University of California Press in 2008.

BAYLEY RAIZ, L.C.S.W., M.B.A., is director of research and quality improvement at Walden House, Inc., one of California's largest behavioral health and human services providers. Mr. Raiz has 8 years of experience as a therapist, supervisor, manager, and consultant in a variety of behavioral health areas and has successfully overseen quality improvement at various organizations.

RICHARD A. RAWSON, PH.D., is associate director of the Integrated Substance Abuse Programs at the University of California, Los Angeles School of Medicine. Dr. Rawson has been a member of the UCLA Department of Psychiatry for more than 20 years. He oversees a portfolio of addiction research ranging from brain imaging studies to numerous clinical trials on pharmacological and psychosocial addiction treatments, as well as the study of how new treatments are applied in the treatment system. During the past decade, he has worked with the U.S. State Department on large substance abuse research and treatment projects that export U.S. technology and addiction science to Mexico, Thailand, Israel, Egypt, and the Palestinian Authority. Dr. Rawson serves on the *Science & Practice Perspectives* Editorial Board.

EWA STAMPER, PH.D., is a clinical psychologist and a member of the Hawaii Psychological Association. Dr. Stamper is in private practice in Kailua, Hawaii. Her areas of expertise include substance abuse, trauma, and depression.